{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:34:06Z","timestamp":1790760846039,"version":"4.1.0"},"reference-count":112,"publisher":"BMJ","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gut"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:p>Interleukin 13 (IL-13) is a cytokine of increasing interest to gastroenterologists because of its developing role in ulcerative colitis, eosinophilic oesophagitis (EO) and fibrosis. Recent data show that IL-13 may play an important role in a novel innate immune response since it can be released by signals from an injured or inflamed epithelium, of particular relevance to the gut. Animal models of IL-13-driven inflammation (from asthma to colitis and EO) are being translated to human disease and providing insight into potential strategies for new therapies. In fact, multiple clinical trials using anti-IL-13 drugs are underway in asthma and are being extended to gastrointestinal diseases. This review presents the current knowledge on IL-13 production and function in the gut, including the cells and receptor signalling pathways involved in mediating IL-13 effects, the proposed mechanisms of IL-13 induced gut disease and the many drugs currently being tested that target IL-13 related pathways.<\/jats:p>","DOI":"10.1136\/gutjnl-2012-303461","type":"journal-article","created":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T20:39:56Z","timestamp":1346531996000},"page":"1765-1773","source":"Crossref","is-referenced-by-count":102,"title":["Interleukin 13 and its role in gut defence and inflammation"],"prefix":"10.1136","volume":"61","clinical-trial-number":[{"clinical-trial-number":"nct00930163","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01545440","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01545453","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00873860","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01482884","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00584584","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01130064","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01266135","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01568762","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01316601","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01022970","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00986037","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00725582","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00410280","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01284062","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01081691","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Peter","family":"Mannon","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, Division Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2012,9,1]]},"reference":[{"key":"2025121304445240000_61.12.1765.1","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.4049\/jimmunol.150.12.5436","article-title":"Structural comparison and chromosomal localization of the human and mouse IL-13 genes","volume":"150","author":"McKenzie","year":"1993","journal-title":"J Immunol"},{"key":"2025121304445240000_61.12.1765.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308327100"},{"key":"2025121304445240000_61.12.1765.3","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200838890"},{"key":"2025121304445240000_61.12.1765.4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200419836"},{"key":"2025121304445240000_61.12.1765.5","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxn060"},{"key":"2025121304445240000_61.12.1765.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(98)70140-X"},{"key":"2025121304445240000_61.12.1765.7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1189\/jlb.72.4.769","article-title":"Human eosinophils express and release IL-13 following CD28-dependent activation","volume":"72","author":"Woerly","year":"2002","journal-title":"J Leukoc Biol"},{"key":"2025121304445240000_61.12.1765.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03413.x"},{"key":"2025121304445240000_61.12.1765.9","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000450"},{"key":"2025121304445240000_61.12.1765.10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912678107"},{"key":"2025121304445240000_61.12.1765.11","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21175"},{"key":"2025121304445240000_61.12.1765.12","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0979-x"},{"key":"2025121304445240000_61.12.1765.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00243-6"},{"key":"2025121304445240000_61.12.1765.14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1201042109"},{"key":"2025121304445240000_61.12.1765.15","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2104"},{"key":"2025121304445240000_61.12.1765.16","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1711.2003.t01-1-01163.x"},{"key":"2025121304445240000_61.12.1765.17","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.24.17193"},{"key":"2025121304445240000_61.12.1765.18","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00089.2003"},{"key":"2025121304445240000_61.12.1765.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1367OC"},{"key":"2025121304445240000_61.12.1765.20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M209560200"},{"key":"2025121304445240000_61.12.1765.21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100467"},{"key":"2025121304445240000_61.12.1765.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2003.08.006"},{"key":"2025121304445240000_61.12.1765.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2006.06.041"},{"key":"2025121304445240000_61.12.1765.24","first-page":"1103","article-title":"IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells","volume":"62","author":"Rahaman","year":"2002","journal-title":"Cancer Res"},{"key":"2025121304445240000_61.12.1765.25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-4090"},{"key":"2025121304445240000_61.12.1765.26","doi-asserted-by":"publisher","DOI":"10.1038\/nm1332"},{"key":"2025121304445240000_61.12.1765.27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3592"},{"key":"2025121304445240000_61.12.1765.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.06.022"},{"key":"2025121304445240000_61.12.1765.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.06.076"},{"key":"2025121304445240000_61.12.1765.30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.11.7905"},{"key":"2025121304445240000_61.12.1765.31","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1997.0270"},{"key":"2025121304445240000_61.12.1765.32","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M108109200"},{"key":"2025121304445240000_61.12.1765.33","first-page":"174","article-title":"Cellular localization of interleukin 13 receptor alpha2 in human primary bronchial epithelial cells and fibroblasts","volume":"18","author":"Konstantinidis","year":"2008","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025121304445240000_61.12.1765.34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.19.10800"},{"key":"2025121304445240000_61.12.1765.35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.214965"},{"key":"2025121304445240000_61.12.1765.36","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2011.224568"},{"key":"2025121304445240000_61.12.1765.37","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.4049\/jimmunol.160.7.3453","article-title":"A critical role for IL-13 in resistance to intestinal nematode infection","volume":"160","author":"Bancroft","year":"1998","journal-title":"J Immunol"},{"key":"2025121304445240000_61.12.1765.38","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80477-X"},{"key":"2025121304445240000_61.12.1765.39","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/iai.64.8.2950-2954.1996","article-title":"Antibody-independent effector mechanisms in resistance to the intestinal nematode parasite Trichuris muris","volume":"64","author":"Else","year":"1996","journal-title":"Infect Immun"},{"key":"2025121304445240000_61.12.1765.40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002520"},{"key":"2025121304445240000_61.12.1765.41","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102216"},{"key":"2025121304445240000_61.12.1765.42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0803868"},{"key":"2025121304445240000_61.12.1765.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.11.043"},{"key":"2025121304445240000_61.12.1765.44","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.09.047"},{"key":"2025121304445240000_61.12.1765.45","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/TP.0b013e31820c861a","article-title":"Interleukin-13 protects mouse intestine from ischemia and reperfusion injury through regulation of innate and adaptive immunity","volume":"91","author":"Farmer","year":"2011","journal-title":"Transplantation"},{"key":"2025121304445240000_61.12.1765.46","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1996.39750.x"},{"key":"2025121304445240000_61.12.1765.47","first-page":"714","article-title":"Interleukin-13 inhibits nitric oxide production in human colonic mucosa","volume":"47","author":"Kolios","year":"2000","journal-title":"Hepatogastroenterology"},{"key":"2025121304445240000_61.12.1765.48","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.491"},{"key":"2025121304445240000_61.12.1765.49","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21133"},{"key":"2025121304445240000_61.12.1765.50","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"key":"2025121304445240000_61.12.1765.51","doi-asserted-by":"crossref","unstructured":"Scharl M Frei S Pesch T . Interleukin-13 and transforming growth factor beta synergise in the pathogenesis of human intestinal fistulae. Gut Published Online First: 27 Jan 2012. doi:10.1136\/gutjnl-2011-300498","DOI":"10.1136\/gutjnl-2011-300498"},{"key":"2025121304445240000_61.12.1765.52","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.5.3207"},{"key":"2025121304445240000_61.12.1765.53","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1004159"},{"key":"2025121304445240000_61.12.1765.54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0802465105"},{"key":"2025121304445240000_61.12.1765.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106469"},{"key":"2025121304445240000_61.12.1765.56","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201008-1210OC"},{"key":"2025121304445240000_61.12.1765.57","doi-asserted-by":"publisher","DOI":"10.1002\/art.24432"},{"key":"2025121304445240000_61.12.1765.58","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1100504"},{"key":"2025121304445240000_61.12.1765.59","doi-asserted-by":"publisher","DOI":"10.1002\/art.30489"},{"key":"2025121304445240000_61.12.1765.60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.10.1929"},{"key":"2025121304445240000_61.12.1765.61","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00453-3"},{"key":"2025121304445240000_61.12.1765.62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20110522"},{"key":"2025121304445240000_61.12.1765.63","doi-asserted-by":"crossref","unstructured":"Camelo A Barlow JL Drynan LF . Blocking IL-25 signalling protects against gut inflammation in a type-2 model of colitis by suppressing nuocyte and NKT derived IL-13. J Gastroenterol Published Online First: 27 Apr 2012. doi: 10.1007\/s00535-012-0591-2","DOI":"10.1007\/s00535-012-0591-2"},{"key":"2025121304445240000_61.12.1765.64","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21628"},{"key":"2025121304445240000_61.12.1765.65","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.08.040"},{"key":"2025121304445240000_61.12.1765.66","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20020906"},{"key":"2025121304445240000_61.12.1765.67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200522818"},{"key":"2025121304445240000_61.12.1765.68","doi-asserted-by":"publisher","DOI":"10.1002\/gepi.10182"},{"key":"2025121304445240000_61.12.1765.69","doi-asserted-by":"publisher","DOI":"10.1007\/s00251-006-0135-0"},{"key":"2025121304445240000_61.12.1765.70","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/9.4.549"},{"key":"2025121304445240000_61.12.1765.71","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.25.3.4483"},{"key":"2025121304445240000_61.12.1765.72","first-page":"789","article-title":"(The significance of IL-13 gene +2044G\/A mutation in patients with inflammatory bowel disease)","volume":"145","author":"Waterman","year":"2006","journal-title":"Harefuah"},{"key":"2025121304445240000_61.12.1765.73","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2009.178665"},{"key":"2025121304445240000_61.12.1765.74","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.11215"},{"key":"2025121304445240000_61.12.1765.75","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.226860"},{"key":"2025121304445240000_61.12.1765.76","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.03.001"},{"key":"2025121304445240000_61.12.1765.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastro.2003.07.007"},{"key":"2025121304445240000_61.12.1765.78","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.027"},{"key":"2025121304445240000_61.12.1765.79","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1000471"},{"key":"2025121304445240000_61.12.1765.80","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2009.03419.x"},{"key":"2025121304445240000_61.12.1765.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.10.039"},{"key":"2025121304445240000_61.12.1765.82","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2010.03606.x"},{"key":"2025121304445240000_61.12.1765.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.03.046"},{"key":"2025121304445240000_61.12.1765.84","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903069"},{"key":"2025121304445240000_61.12.1765.85","doi-asserted-by":"publisher","DOI":"10.1159\/000082331"},{"key":"2025121304445240000_61.12.1765.86","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-002-0684-z"},{"key":"2025121304445240000_61.12.1765.87","doi-asserted-by":"publisher","DOI":"10.1172\/JCI7325"},{"key":"2025121304445240000_61.12.1765.88","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-2249.1995.tb03131.x","article-title":"A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with cryptogenic fibrosing alveolitis (CFA)","volume":"101","author":"Wallace","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"2025121304445240000_61.12.1765.89","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5909"},{"key":"2025121304445240000_61.12.1765.90","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2008.85"},{"key":"2025121304445240000_61.12.1765.91","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.6.809"},{"key":"2025121304445240000_61.12.1765.92","doi-asserted-by":"publisher","DOI":"10.1136\/gut.5.1.1"},{"key":"2025121304445240000_61.12.1765.93","doi-asserted-by":"publisher","DOI":"10.1136\/gut.33.7.938"},{"key":"2025121304445240000_61.12.1765.94","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-011-0789-4"},{"key":"2025121304445240000_61.12.1765.95","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.049"},{"key":"2025121304445240000_61.12.1765.96","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2009.01396.x"},{"key":"2025121304445240000_61.12.1765.97","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2008.01220.x"},{"key":"2025121304445240000_61.12.1765.98","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01659.x"},{"key":"2025121304445240000_61.12.1765.99","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.136515"},{"key":"2025121304445240000_61.12.1765.100","doi-asserted-by":"publisher","DOI":"10.2217\/imt.12.28"},{"key":"2025121304445240000_61.12.1765.101","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.630"},{"key":"2025121304445240000_61.12.1765.102","doi-asserted-by":"crossref","unstructured":"Piper E Brightling C Niven R . Phase 2 randomized, double-blind, placebo-controlled study of tralokinumab, an anti-IL-13 monoclonal antibody, in moderate to severe asthma. Eur Respir J Published Online First: 27 Jun 2012. doi:10.1183\/09031936.00223411 abstract 3425.","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A2759"},{"key":"2025121304445240000_61.12.1765.103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.05.013"},{"key":"2025121304445240000_61.12.1765.104","first-page":"A6644","article-title":"ABT-308, A highly potent anti-IL-13 therapeutic antibody for the treatment of human asthma","volume":"181","author":"Ying","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121304445240000_61.12.1765.105","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1448OC"},{"key":"2025121304445240000_61.12.1765.106","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-011-0481-y"},{"key":"2025121304445240000_61.12.1765.107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61600-6"},{"key":"2025121304445240000_61.12.1765.108","first-page":"A6179","article-title":"A phase 2b study of inhaled pitrakinra, an IL-4\/IL-13 antagonist, successfully identified responder subpopulations of patients with uncontrolled asthma","volume":"183","author":"Otulana","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121304445240000_61.12.1765.109","unstructured":"Wenzel SE Ind PW Otulana BA . Inhaled pitrakinra, an IL-4\/IL-13 antagonist, reduced exacerbations in patients with eosinophilic asthma. Eur Resp Soc Annual Congress 2010:abstract 3980."},{"key":"2025121304445240000_61.12.1765.110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.08.001"},{"key":"2025121304445240000_61.12.1765.111","unstructured":"Hodges M Castelloe E Chen A . A phase 1 multiple dose safety and pharmacokinetics study of AIR645, an inhaled IL-4r\u03b1 2-MOE GAPMER oligonucleotide. Eur Resp Soc Annual Congress 2009:abstract 1800."},{"key":"2025121304445240000_61.12.1765.112","first-page":"A3640","article-title":"Randomized, double-blind, placebo controlled first in human study of inhaled AIR645, an IL-4R{alpha} oligonucleotide, in healthy volunteers","volume":"179","author":"Hodges","year":"2009","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2012-303461","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T12:44:59Z","timestamp":1765629899000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2012-303461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,1]]},"references-count":112,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,11,9]]},"published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1136\/gutjnl-2012-303461"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2012-303461","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,1]]}}}